Roisin M Connolly
ECOG-ACRIN Cancer Research Group · JHU Sidney Kimmel Comprehensive Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Roisin M Connolly as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06136897 · Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)National Cancer Institute (NCI) · active not recruiting · Malignant Solid Neoplasm · principal investigator
- Ph1NCT02453620 · Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast CancerNational Cancer Institute (NCI) · active not recruiting · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma · principal investigator
- Ph3NCT02115282 · Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or MetastaticNational Cancer Institute (NCI) · active not recruiting · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma · principal investigator
- Ph1NCT01638533 · Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNational Cancer Institute (NCI) · completed · Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026Named on NCT06136897, NCT02115282
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT02453620, NCT01638533
- NCI ETCTN Pittsburgh Cancer Consortium (PCC)UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026Named on NCT02453620, NCT01638533
- The Johns Hopkins Translational Science Team and Consortium for ETCTN StudiesUM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026Named on NCT02453620, NCT01638533
- Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTNUM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026Named on NCT02453620, NCT01638533
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT02115282
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT02115282
- Princess Margaret Hospital Phase I ConsortiumU01CA132123 · NCI · UNIVERSITY HEALTH NETWORK · PI Lillian L Siu · fiscal years 2008 to 2013Named on NCT01638533
- Phase I Molecular and Clincal Pharmacodynamic TrialsU01CA062505 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EDWARD M NEWMAN · fiscal years 1994 to 2013Named on NCT01638533
- Phase I Clinical Trials of Anticancer AgentsU01CA069912 · NCI · MAYO CLINIC ROCHESTER · PI CHARLES ERLICHMAN · fiscal years 1995 to 2013Named on NCT01638533
- Phase I Clinical Trials of New Anti-Cancer Targeted TherapiesU01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael A Carducci · fiscal years 1995 to 2013Named on NCT01638533
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT01638533
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT01638533
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2014 to 2019Named on NCT01638533
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 13:09 UTC. The ranking covers the 200 most relevant of 21 PubMed records, and a shared surname and initials can bring in a namesake. All 21 on PubMed
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.J Clin Oncol · 2019306 citationsRCR 11.1
- Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.Nat Med · 2024219 citationsRCR 25.8
- 137 citationsRCR 4.3
- Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.Clin Cancer Res · 2017132 citationsRCR 4.1
- 121 citationsRCR 7.8
- 111 citationsRCR 5.9
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Nat Cancer · 202454 citationsRCR 6.2
- 52 citationsRCR 1.5
- The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial.Clin Cancer Res · 202044 citationsRCR 2.2
- Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer.J Clin Oncol · 202142 citationsRCR 2.2